Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ondine Biomedical, Inc. ( (GB:OBI) ) has provided an update.
Ondine Biomedical Inc. and Mid Yorkshire Teaching NHS Trust have been shortlisted for the ‘Most Impactful Use of Technology on Clinical Practice’ award at the 2026 HSJ Partnership Awards. This recognition follows the successful implementation of Ondine’s Steriwave® nasal decolonisation technology, which significantly reduced surgical site infections and hospital costs. The technology, which offers an antibiotic-sparing alternative to traditional treatments, is gaining traction across major hospitals in England, potentially saving the NHS up to £200 million annually. The shortlisting underscores the importance of innovative solutions in addressing rising antimicrobial resistance and improving patient outcomes.
The most recent analyst rating on (GB:OBI) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
Spark’s Take on GB:OBI Stock
According to Spark, TipRanks’ AI Analyst, GB:OBI is a Underperform.
Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.
To see Spark’s full report on GB:OBI stock, click here.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology, with its nasal photodisinfection system, Steriwave®, approved in several countries and undergoing clinical trials in the US.
Average Trading Volume: 177,903
Technical Sentiment Signal: Sell
Current Market Cap: £53.13M
See more data about OBI stock on TipRanks’ Stock Analysis page.